CVS Health Corporation $CVS Shares Sold by Gabelli Funds LLC

Gabelli Funds LLC reduced its holdings in CVS Health Corporation (NYSE:CVS) by 13.4% during the fourth quarter, Holdings Channel reports. The firm owned 256,700 shares of the pharmacy operator’s stock after selling 39,610 shares during the period. Gabelli Funds LLC’s holdings in CVS Health were worth $20,372,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in CVS. Sei Investments Co. raised its holdings in shares of CVS Health by 17.4% in the 2nd quarter. Sei Investments Co. now owns 905,715 shares of the pharmacy operator’s stock worth $62,474,000 after purchasing an additional 134,535 shares in the last quarter. The Manufacturers Life Insurance Company raised its holdings in shares of CVS Health by 1.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 1,121,377 shares of the pharmacy operator’s stock worth $77,353,000 after purchasing an additional 13,329 shares in the last quarter. Treasurer of the State of North Carolina raised its holdings in shares of CVS Health by 1.3% in the 2nd quarter. Treasurer of the State of North Carolina now owns 585,073 shares of the pharmacy operator’s stock worth $40,358,000 after purchasing an additional 7,588 shares in the last quarter. HUB Investment Partners LLC raised its holdings in shares of CVS Health by 25.0% in the 2nd quarter. HUB Investment Partners LLC now owns 15,063 shares of the pharmacy operator’s stock worth $1,039,000 after purchasing an additional 3,011 shares in the last quarter. Finally, Alliancebernstein L.P. raised its holdings in shares of CVS Health by 8.0% in the 2nd quarter. Alliancebernstein L.P. now owns 1,609,404 shares of the pharmacy operator’s stock worth $111,017,000 after purchasing an additional 119,439 shares in the last quarter. 80.66% of the stock is currently owned by institutional investors.

CVS Health Stock Up 0.2%

CVS stock opened at $96.07 on Tuesday. CVS Health Corporation has a 52-week low of $58.50 and a 52-week high of $98.43. The company’s 50 day simple moving average is $79.06 and its 200-day simple moving average is $78.66. The company has a debt-to-equity ratio of 0.78, a current ratio of 0.87 and a quick ratio of 0.66. The firm has a market capitalization of $122.58 billion, a P/E ratio of 42.32, a P/E/G ratio of 0.94 and a beta of 0.60.

CVS Health (NYSE:CVS) last released its earnings results on Wednesday, May 6th. The pharmacy operator reported $2.57 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.21 by $0.36. CVS Health had a net margin of 0.72% and a return on equity of 11.88%. The company had revenue of $100.43 billion during the quarter, compared to the consensus estimate of $94.99 billion. During the same quarter in the prior year, the firm earned $2.25 EPS. The company’s revenue was up 6.2% compared to the same quarter last year. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. As a group, equities research analysts anticipate that CVS Health Corporation will post 7.44 EPS for the current year.

CVS Health Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, May 4th. Shareholders of record on Thursday, April 23rd were given a $0.665 dividend. This represents a $2.66 annualized dividend and a yield of 2.8%. The ex-dividend date of this dividend was Thursday, April 23rd. CVS Health’s dividend payout ratio is presently 117.18%.

Analysts Set New Price Targets

CVS has been the topic of a number of research reports. Wells Fargo & Company boosted their target price on shares of CVS Health from $102.00 to $103.00 and gave the stock an “overweight” rating in a report on Friday, May 8th. Argus boosted their target price on shares of CVS Health from $90.00 to $104.00 and gave the stock a “buy” rating in a report on Thursday, May 14th. Leerink Partners reiterated an “outperform” rating and issued a $98.00 target price on shares of CVS Health in a report on Thursday, March 5th. JPMorgan Chase & Co. boosted their price target on shares of CVS Health from $101.00 to $111.00 and gave the company an “overweight” rating in a report on Tuesday, May 12th. Finally, UBS Group boosted their price target on shares of CVS Health from $97.00 to $100.00 and gave the company a “buy” rating in a report on Thursday, May 7th. Twenty-two equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $98.08.

Insiders Place Their Bets

In other CVS Health news, EVP Tilak Mandadi sold 69,551 shares of the company’s stock in a transaction dated Friday, May 8th. The stock was sold at an average price of $89.58, for a total value of $6,230,378.58. Following the transaction, the executive vice president directly owned 10,133 shares of the company’s stock, valued at $907,714.14. This represents a 87.28% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.85% of the stock is currently owned by insiders.

CVS Health Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.